RE:RE:RE:RE:RE:RE:RE:TLT Filling Up With CashIf Theralase is serious about partnering for the eventual rollout of the bladder cancer treatments I would expect they are well into negotiations.
While commercialization is not likely until 2023, if the board consensus is correct, there is a lot of work required to launch successfully. The phase 2 sites will get be easy to transition but there is a lot of time and work to get the equipment, the drug and the training necessary out to all the major hospitals. The sooner there is a partner the better prepared for commercialization after FDA approval.
So my expectation is the company will get Breakthrough Status in 2022 and around that point in time the partnership deal will be announced.
For Theralase the terms of such a deal should provide a large cash infusion based on meeting key milestones and a sharing in the JV/partnership profits.
I am thinking between $50 and $200 million in payments plus 50% of the profits with the partner running the venture.
I would expect an upfront payment on signing the deal followed by a larger chunk on FDA approval and additional sums on meeting sales revenues.
So while commercialization might not come until 2023 shareholders should see a bump in the share price once a deal is announced.
Thoughts??